Fig. 2From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in chinaOverall survival. The curves indicate the model outputs. The diamond and triangle markers indicate the 5-y OS of ACTH and TCH treatmentBack to article page